RxDoctor Payments DataLook up a doctor →

Isaac Beshay, MD

Family Medicine · Costa Mesa, CANPI 1962434241

Payments from drug & device makers

$1,476,620in general payments, 2019–2025

Across 2,320 payments — averaging $636.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$1M
  • AbbVie$359K
  • AstraZeneca$48K
  • Kowa Research Institute, Inc.$26K
  • Bristol Myers Squibb$24K
  • Gilead$7K
  • plus $10K from 52 others
$2,058in research payments, 2019–2025

Across 4 payments — averaging $514.55 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk AS1,592$1,002,902
AbbVie(2 entities)188$358,842
AstraZeneca63$47,767
Kowa Research Institute, Inc.21$25,578
Bristol Myers Squibb5$24,435
Gilead11$6,847
Lilly USA, LLC61$1,325
Novo Nordisk34$982
Astellas Pharma US Inc40$859
Pfizer26$604
Boehringer Ingelheim26$561
GSK24$551
Amgen14$546
Harmony Biosciences LLC17$502
Novartis16$330
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)18$326
Phathom Pharmaceuticals, Inc.6$317
Johnson & Johnson10$314
Abbott11$283
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC17$267
IBSA Pharma Inc.4$197
Eisai Inc.14$179
Bayer8$169
Biohaven Pharmaceutical Holding Company Ltd.8$165
Vanda Pharmaceuticals Inc.6$157
Redhill Biopharma Inc.7$148
UCB, Inc.4$145
Merck8$134
Insulet Corporation4$133
Sanofi-aventis U.S. LLC7$128
Takeda Pharmaceuticals U.S.A., Inc.7$113
Genentech USA, Inc.4$69
Amarin Pharma, Inc.3$61
Sunovion Pharmaceuticals Inc.4$59
Mannkind Corporation3$56
Exact Sciences2$48
Teva Pharmaceuticals USA, Inc.2$41
Idorsia Pharmaceuticals US Inc2$38
Alkermes, Inc.2$37
Merz North America, Inc.1$36
Dexcom, Inc.2$33
Xeris Pharmaceuticals, Inc.2$32
Theratechnologies Inc.1$26
Edwards Lifesciences1$25
Corcept Therapeutics1$24
Alk-abello, Inc1$23
Sun Pharmaceutical Industries Inc.1$23
Endo Pharmaceuticals Inc.1$21
Inspire Medical Systems, Inc.1$21
Cipher Pharmaceuticals US LLC1$21
Coopersurgical, Inc.1$20
Meridian Bioscience Inc.1$18
Phadia US Inc.1$18
Scilex Pharmaceuticals Inc.1$18
Boston Scientific1$17
Otsuka America Pharmaceutical, Inc.1$17
Medtronic1$12
Sumitomo Pharma America, Inc.1$1

How this compares

$1,476,620 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California →

Medicare billing

Part B allowed, 2024
$50,324
Medicare patients
125
Services billed
429

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other family medicine in Costa Mesa

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →